Sept 05, 2007 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) : it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, picoplatin, for the second-line treatment of refractory or resistant small cell lung cancer (SCLC)... Read the Poniard Pharmaceuticals' Press Release -
Blog Archive
-
▼
2007
(90)
-
▼
September
(43)
- Oncolytics Biotech, Phase Ia/Ib Combination REOLYS...
- Gene Express, Lung Cancer Diagnostic
- The SFDA of the PRC Grants Immtech Fast Track Status
- Spiration, U.S. Pivotal Trial of Minimally Invasiv...
- Alkermes and Indevus, Positive Results from Phase ...
- Curis , Development Candidate CUDC-101 and Its Tar...
- Inspired Technologies, FDA 510(k) Approval for the...
- Pharmacopeia , Phase 1 Clinical Trials of a poten...
- Cell Therapeutics, Gender-Specific Phase III Trial...
- Encysive Pharmaceuticals, Phase III Study With The...
- Progen , PI-88 Phase 2 Lung Cancer Results
- ImClone , Expands IMC-A12 Development with Ten New...
- Lilly, ALIMTA® (pemetrexed for injection) for Firs...
- Nymox Saliva Test, Saliva NicAlert, test for tobac...
- OSI Pharmaceuticals, Patent Term Extension for Tar...
- LigoCyte , to develop therapies targeting CD103 fo...
- Forest Laboratories, single doses of inhaled aclid...
- Biomoda, Inc. and TriCore, detection of early lung...
- Replidyne's Phase III clinical program for the tre...
- Exelixis Submits XL880 Diligence Report to GlaxoSm...
- Genmab,Target and Development Plans for HuMax-Inflam
- Illumina, Genotyping Service Agreement with Leadin...
- Seegene, Diagnostic Test Kit Capable of Detecting ...
- GeneGo and the Cystic Fibrosis Foundation Collabor...
- ImClone and BMS, ERBITUX ,Primary Endpoint of Incr...
- China Kangtai Cactus Biotech, Cactus Health Cigare...
- Novelos Therapeutics, 5th U.S. Patent
- Accuray, FDA Clearance for New Dose Calculation Te...
- TapImmune, Initiation of Testing on Novel Cancer V...
- Perceptronix, Launch of LungSign(TM)
- TOPIGEN Pharmaceuticals, TPI 1020 Into Phase 2 Dev...
- OSI Pharmaceuticals, Data Presented on Tarceva(R) ...
- superDimension, First Device to Enable Minimally-I...
- Aradigm and CyDex, Development Collaboration Agree...
- Amgen , Aranesp(R) Study Showing No Negative Impac...
- Idera Pharmaceuticals, Phase 1 Study Evaluating
- Introgen Therapeutics, Immunotherapy Drug [p53] C...
- Pharmacyclics , Phase 2 Data With Xcytrin(R) in Re...
- Biomira Inc., Stimuvax(R) Phase II data highlight,...
- Nabi Biopharmaceuticals, Positive NicVAX (Nicotine...
- Poniard Pharmaceuticals Picoplatin for Treatment o...
- Pfizer Oncology, Advanced Non-Small Cell Lung Cancer
- A blog about Lung's Diseases
-
▼
September
(43)
Sep 7, 2007
Poniard Pharmaceuticals Picoplatin for Treatment of Small Cell Lung Cancer
Sept 05, 2007 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) : it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, picoplatin, for the second-line treatment of refractory or resistant small cell lung cancer (SCLC)... Read the Poniard Pharmaceuticals' Press Release -
